- The ENCOMPASS study surveyed 400 adults, 200 adolescents, and 200 dermatology providers on psoriasis care.
- 55% of adults and over 70% of adolescents reported a very large QoL impact from psoriasis.
- Oral treatments were preferred by 50.5% of patients and 47.5% of healthcare providers.
- 91.2% of patients on injectables are willing to switch to effective oral treatments.
Study Overview
The ENCOMPASS study, presented at the 2025 Fall Clinical Dermatology Conference, surveyed 400 adults, 200 adolescents with psoriasis, and 200 dermatology providers. It aimed to evaluate patient and healthcare provider perspectives on barriers and unmet needs in psoriasis care.
Quality of Life Impact
Findings revealed that psoriasis significantly affects quality of life (QoL). Over half of adult patients reported a very large or extremely large QoL impact, while over 70% of adolescents experienced similar effects. The disease burden was influenced by skin symptoms, severity, lesion location, lack of effective treatments, and impacts on social activities and mental health.
Treatment Preferences
The study highlighted a strong preference for oral treatments among both patients and healthcare providers. Oral treatments were preferred by 50.5% of patients and 47.5% of providers, followed by topicals and injectables. A significant 91.2% of patients currently using injectables expressed willingness to switch to an equally effective oral treatment with a favorable safety profile.
